Tripep signs a Letter of Intent with San Diego based Inovio Inc for a joint clinical development of ChronVac-B, a therapeutic vaccine for chronic hepatitis B virus infections
October 04, 2007 02:12 ET
|
Fastilium Property Group AB
Tripep signs a Letter of Intent with San Diego based Inovio Inc for a joint
clinical development of ChronVac-B, a therapeutic vaccine for chronic hepatitis
B virus infections
Tripep and San...
Tripep tecknar Letter of Intent med USA-baserade Inovio Inc för ytterligare ett gemensamt klinisk utvecklingsprojekt; ChronVac-B, ett behandlande vaccin mot kronisk hepatit B-virusinfektion
October 04, 2007 02:08 ET
|
Fastilium Property Group AB
Tripep tecknar Letter of Intent med USA-baserade Inovio Inc för ytterligare ett
gemensamt klinisk utvecklingsprojekt; ChronVac-B, ett behandlande vaccin mot
kronisk hepatit B-virusinfektion
Tripep...
Interim Report January - June 2007 Tripep AB (publ)
August 24, 2007 01:53 ET
|
Fastilium Property Group AB
Interim Report January - June 2007 Tripep AB (publ)
• Research and development costs amounted to SEK 7.7 million
• The loss after tax was SEK 13.8 million
• Earnings per share were SEK 0.29
• The...
Delårsrapport januari - juni 2007 Tripep AB (publ)
August 24, 2007 01:51 ET
|
Fastilium Property Group AB
Delårsrapport januari - juni 2007 Tripep AB (publ)
• Forsknings- och utvecklingskostnader 7,7 MSEK
• Resultat efter skatt -13,8 MSEK
• Resultat per aktie -0,29 SEK
• Bolaget hade ingen omsättning...
Tripep has received approval to start a phase I/II study of the ChronVac-C® vaccine as a treatment for chronic infections by the hepatitis C virus
August 15, 2007 09:14 ET
|
Fastilium Property Group AB
Tripep has received approval to start a phase I/II study of the ChronVac-C®
vaccine as a treatment for chronic infections by the hepatitis C virus
Tripep has received approval to start a clinical...
Tripep har fått godkänt att inleda fas I/II-studie av ChronVac-C® som behandling av kronisk hepatit C virusinfektion
August 15, 2007 09:10 ET
|
Fastilium Property Group AB
Tripep har fått godkänt att inleda fas I/II-studie av ChronVac-C® som behandling
av kronisk hepatit C virusinfektion
Tripep har av Läkemedelsverket fått godkänt att inleda en klinisk fas
I/II-studie...
Tripep has received patent protection for administration of ChronVac-C® vaccine using electroporation
May 30, 2007 09:04 ET
|
Fastilium Property Group AB
Tripep has received patent protection for administration of ChronVac-C® vaccine
using electroporation
Yesterday, Tripep received a patent in the USA for use of the ChronVac-C®
vaccine, administered...
Tripep har erhållit patentskydd för administrering av ChronVac-C®-vaccin i kombination med elektroporering
May 30, 2007 09:02 ET
|
Fastilium Property Group AB
Tripep har erhållit patentskydd för administrering av ChronVac-C®-vaccin i
kombination med elektroporering
Tripep erhöll igår patent i USA för ChronVac-C®-vaccin, som ges i kombination
med ett...
Tripep initiates preparations for a phase I/II study of ChronVac-C® vaccine
May 21, 2007 08:56 ET
|
Fastilium Property Group AB
Tripep initiates preparations for a phase I/II study of ChronVac-C® vaccine
Following the advice from the Swedish Medical Products Agency (MPA) Tripep has
started the preparations for a phase I/II...
Tripep inleder förberedelser för en fas I/II-studie av ChronVac-C®-vaccin
May 21, 2007 08:54 ET
|
Fastilium Property Group AB
Tripep inleder förberedelser för en fas I/II-studie av ChronVac-C®-vaccin
På inrådan från Läkemedelsverket (LMV) har Tripep inlett förberedelserna för en
klinisk fas I/II-studie av sitt...